Targeting adenoviral vectors and replicative oncolytic adenoviruses to specific cell types is the most important requirement to reduce their toxicity and increase their efficacy after systemic administration. Targeting can be achieved by interfering at the level of capsid binding or at later transduction events such as gene expression. Targeting at the level of binding is preferred since even the interaction of cells with empty capsids leads to toxic effects. 1 This targeting approach requires eliminating the undesired binding properties of the current adenoviral vectors and providing a new selective ligand to the virus. The latter has been conferred using bispecific conjugates that link the virus to the target cell or using genetic modifications of the capsid that directly introduce the new ligand. [2] [3] [4] On the other hand, the ablation of the binding of adenoviral vectors to its primary cellular receptor, the coxsackie-adenovirus receptor CAR, has been achieved by deleting specific residues on the knob domain of the fiber. 5 In this study, we have evaluated the effect of such a deletion on vector biodistribution and toxicity. Intravenous injection of unmodified CAR-binding vectors leads mainly to transgene expression in liver. This has been explained by a combination of endothelial fenestrations and CAR levels. 6 Despite the ablation of CARbinding we have found that its biodistribution and the subsequent liver toxicity are preserved. This implies that further deletions in the viral capsid are necessary to impact on adenovirus targeting.
Residue Y477 in the DE loop of the fiber is critical for CAR binding. 5 Mutation of this tyrosine to alanine results in ablation of CAR-binding. Although several other mutations have been described that affect lysines or introduce glutamic acid residues, we chose Y477A in part to avoid increasing the negative charge of the capsid, a property that could affect blood persistence. 7 The Y477A mutation was introduced in the viral genome through a series of homologous recombination steps. In a final recombination step, the E1 region was substituted for a double expression cassette encoding GFP and luciferase. CAR-binding (AdGFPLuc) and CAR-binding ablated (AdGFPLucY477A) vectors were produced in 293 cells by transfection of the corresponding viral genome isolated from the plasmids (following previous nomenclature we use the short name of 'CAR-ablated' instead of the proper CAR-binding ablated description 4 ). To prevent a possible propagation inefficiency of the CAR-ablated vector in 293 cells we also constructed a GFP/luciferase vector with a fiber containing Y477A and a 6 × histidine carboxy-terminal tag (AdGFPLucY477Ax6H) to be propagated in 293.HissFv.rec. 8 However, using standard propagation conditions (20-fold amplification at every passage), AdGFPLucY477A could be propagated in 293 without difficulty provided a longer time for complete cpe was allowed (3 days instead of 2). This propagation capability is in agreement with the CAR-independent infectivity mediated by penton base attachment to ␣v integrins. 4, 9 In fact, the differences in propagation efficiency of the CARbinding and CAR-ablated vectors reflect the contribution of CAR-binding in viral infectivity. To quantitate these infectivity differences properly we performed a cpe assay whereby cell lysis is measured as a decrease in total cell protein concentration.
10 Figure 1 shows the titration in 293 cells of CAR-binding AdGFPLuc and CAR-ablated AdGFPLucY477A vectors from viral stocks of the same concentration (10 12 viral particles/ml). The 50% cell lysis level is obtained at the 4 × 10 −4 dilution for the CARablated vector and at the 4 × 10 −7 dilution for the CARbinding vector. This indicates that a three-log decrease of infectivity can be attributed to CAR ablation. Another assay for infectivity is the quantification of transducing events (units) produced by each vector. The number of green fluorescent cells was counted 18 h after infection of 293 cells with serial dilutions of each vector. For the CARbinding vector we estimated a titer of 3.2 × 10 10 transducing units/ml which yields an estimated bioactivity of 1 transducing unit every 31 viral particles. For the CARablated vector the titer was 2 × 10 8 transducing units/ml or 1 bioactive transducing unit every 5000 particles. In bioactive transducing units therefore the difference between the CAR-binding and CAR-ablated virus was of 160 times. The transducing assay therefore proved less sensitive than the cpe assay to detect the diferential infectivity of the CAR-binding versus the CAR-ablated vectors. This is probably due to the longer incubation times and the amplification rounds of the cpe assay. 11 We also measured the transduction efficiency of the CAR-ablated vectors with or without the 6×His tag in comparison to the CAR-binding vector on 293 cells expressing or not the artificial receptor for the tag (Figure 1b) . In 293 cells, the two CAR-ablated vectors (with or without the 6×His tag) showed about two logs lower transduction efficiency than the CAR-binding vector. In 293 cells expressing the 6×his receptor, the CAR-ablated vector containing the 6×His tag achieved levels of transduction similar to the CAR-binding vector. The cells with the artificial receptor represent therefore a valuable tool to detect functional units of the CAR-ablated and CAR-binding vectors with similar sensitivity.
Although it is unlikely that the inhibition of gene transfer induced by the Y477A mutation in the fiber knob occurred at a post-binding step, we performed an ELISA to determine the binding of CAR to each vector. After adsorption of the corresponding vector to the plate, different amounts of soluble CAR were added to the wells and the bound CAR was detected with and anti-CAR antibody. The results indicate a marked binding defect of the mutated vector to CAR (Figure 1c) .
To confirm that Y477A ablates CAR recognition and that the transducing events observed with this CARablated vector were not a consequence of residual binding to CAR, we took the same number of transducing units of each vector (which implies 160 times more viral particles for the CAR-ablated vector) and performed a competition assay with purified knob. As shown in Figure 2 , the presence of soluble knob inhibited the infectivity of the CAR-binding vector but not the infectivity of the CAR-ablated vector. This finding demonstrates a CAR-independent entry mechanism in agreement with previous reports. 4, 9 As CAR-ablated vectors could be utilizing integrins for infection, we compared the transduction efficiency of CAR-binding and ablated vectors in the presence of anti-integrin antibodies (Figure 2c, d) . At the concentration of antibody used, the transduction with the CAR-ablated vector was much more susceptible to inhibition than the transduction with the CAR-binding vector (80% versus 5%). This corroborates the assumption that the integrin-mediated entry pathway is at least partially responsible for the infectivity of CAR-ablated vectors. Other receptors such as the MHC or heparan sulfate glycosaminoglycans could also contribute to their infectivity. 12, 13 To compare the biodistribution of CAR-binding and CAR-ablated vectors we injected 5 × 10 10 viral particles of each vector in C57BL/6 mouse via tail vein. Despite the heterogeneity of previous biodistribution studies, this dose and strain were used to try and allow as much comparison to previous studies as possible. 6, 14, 15 At an early time-point, 90 min after injection, we measured the amount of viral DNA in lung, kidney and liver using quantitative Taq-Man PCR. Most of the viral DNA was detected in the liver for both the CAR-binding and CARablated vectors (Figure 3a) . We assume that most of the injected vector localizes in macrophages of the reticuloendothelial system, mainly Kupffer cells via a CAR-independent entry mechanism. 4, 7, 16 Therefore, if any biodistriGene Therapy bution change due to CAR ablation is expected, this should be reflected at later time-points. Figure 3b shows the luciferase expression levels in different tissues 3 days after injection of 5 × 10 10 particles of each vector. A wide variety of organs were transduced, with a distribution pattern matching previous reports. 17, 18 The majority of luciferase activity was detected in the liver with levels three or more orders of magnitude higher than in other tissues. Most importantly, in liver no transduction differences were found between CAR-binding and CARablated vectors. Secondary to the liver, the spleen and the ovary were the organs where more luciferase expression was detected. Among these, the expression in ovary was reduced when using the CAR ablated vector. Among other tissues with even lower levels of expression, the only other organ in which CAR ablation negatively affected luciferase expression was the heart. In this regard, it is interesting to note the high levels of CAR in heart. 6 Due to the importance of liver transduction for targeting issues, we examined liver sections to determine whether the cells types transduced with the CAR-binding and ablated vectors might be different. Figure 4 shows expressing cells when combined with bright GFP forms (in this case EGFP from Clontech, Palo Alto, CA, USA). 19 In both cases the fluorescent cells detected corresponded to hepatocytes, clearly distinguished by their size, round nuclei and intersinusoidal localization. These results, taken together with the observation that the viral uptake mediated by Kupffer cells does not lead to transgene expression 20 and that a similar lack of transduction permissivity is found in sinusoidal endothelial cells, 21 indicate that hepatocytes are the cell type responsible for the observed luciferase and GFP transduction.
Figure 3 Biodistribution of CAR-binding and CAR-ablated vectors. (a) Distribution of viral DNA 90 min after injection. 5 × 10 10 Viral particles of CAR-binding AdGFPLuc or CAR-ablated AdGFPLucY447A vector were injected via tail vein into C57/BL6 mice (four mice per group). A negative control group was injected with PBS. Ninety minutes after injection lung, kidney and liver were processed for DNA extraction using
The fate of most of the intravenously injected adenovirus is the macrophages of the liver and spleen. 16 We previously studied the clearance rates of unmodified vectors in mice and found that more than 99.9% of the circulating virus was removed in the first hour after injection with a half life of less than 2 min. 7 The binding interactions responsible for this clearance are unknown and, therefore, a role for CAR cannot be excluded. We have used the CAR-ablated vector AdGFPLucY477A-6His to measure the contribution of CAR-binding to this clearance. We injected 2 × 10 10 viral particles of AdGFPLucY477A-6His or AdGFPLuc into the cava vein of C57BL/6 mice. At different times after injection an aliquot of blood was collected from the tail vein in heparinized Eppendorf tubes and serially diluted in PBS to measure the amount of transducing units by infection of 293.HissFv.rec cells. An aliquot of each viral preparation was also taken before injection (time 0) to control that the amount of injected transducing units was the same. From the earliest time-point measured, 1 min after injection, the level of CAR-ablated vector detected was 10-fold higher than the CAR-binding vector ( Figure 5) . Interestingly, the slope of the clearance curve was similar for both vectors. This suggests a high affinity saturable CAR-mediated binding combined with a lower affinity non-saturable CAR-independent binding. CAR ablation, therefore, results in a higher level of circulating vector at each timepoint. If we consider that the CAR-ablated vector can still infect through an integrin-mediated pathway, this higher level of circulating vector could compensate for its lower infectivity and could explain the similar transduction pattern of CAR-ablated and CAR-binding vectors. It has been shown in vitro that the increase in the transduction with absorption time follows a logaritmic curve. 11 At short absorption times the number of transduction events greatly increases if the incubation time slightly increases and at long adsorption times this dependence on time disappears. Therefore, the fact that the virus is cleared so rapidly means that a slight increase in blood persistence is expected to result in major changes in transduction.
The infection of different types of liver cells, such as Kupffer cells, endothelial cells, and hepatocytes, which follows the intravenous administration of adenoviral vec-tors leads to an inflammatory response that can be divided into two phases: an immediate response independent of viral gene expression initiated during the first 24 h after injection, and a late phase that depends on gene expression and that develops several days after injection. The early response is mediated by chemokines MIP-2, MCP-1 and IP-10, produced by Kupffer cells and hepatocytes, and other cytokines such as TNF␣ produced mainly by Kupffer cells and IL-6 produced by Kupffer cells, endothelial cells and hepatocytes. 1, 22 The activation of NF-B in hepatocytes further stimulates the production of TNF␣ and IL-6. These cytokines induce the influx of neutrophils, NK cells, and monocyte-macrophages that will prime the development of the late specific adaptive immune response characterized by a lymphocytic infiltration that is cytotoxic against transduced cells expressing viral genes or immunogenic transgenes. The early acute toxicity causes both necrotic and apop- totic cell death in contrast to the CTL-mediated lysis of infected cells during the late phase. However, in both phases there is a release of liver transaminases. In theory, if we abrogate the binding of vector to liver cells, we expect both phases of vector-associated toxicity to diminish. To determine whether CAR-binding ablation decreases liver toxicity, we injected 5 × 10 10 viral particles of the CAR-ablated vector AdGFPLucY477A or the CARbinding vector AdGFPLuc intravenously in C57BL/6 mice and examined the liver histopathology and serum transaminases levels. This toxicity analysis was done at day 5 after injection because at this time-point a peak of adenovirus-mediated toxicity occurs in C57BL/6 mice, reflected by monocyte-lymphocyte infiltration, hepatocyte swelling and shrinkage, and the release of transaminases to the serum. 15 Our pathological analysis revealed that the CAR-binding and CAR-ablated vector induced similar levels of necrosis, hepatocyte dystrophy and neutrophil/lymphocyte infiltration ( Figure 6 ). Corroborating this similar toxicity, ALT and AST levels increased 10-fold with both vectors. These results are consistent with the similar levels of transduction achieved with CAR-binding and CAR-ablated vectors.
In summary, the data we present indicate that the ablation of CAR-binding is not sufficient to change the biodistribution of adenoviral vectors. The residual CARindependent infectivity of the vector combined with an increased blood persistence are likely to preserve the vector hepatotropism and associated hepatotoxicity. The ablation of the RGD sequence of the penton base is the next clear step towards untargeting the liver. However, the possibility remains that even then other binding properties of the viral capsid different from CAR and ␣v integrins could induce secretion of cytokines and hepatic toxicity. 23 
